Biotech
The GLP-1 trade is not over - it's changing shape
Ozempic minted the first wave. The second wave is where the alpha is.
Novo and Lilly captured the headlines. The next leg is manufacturing, delivery mechanisms, and the second-order winners - cardiac risk, kidney disease, addiction. Watch the mid-cap contract manufacturers.
#glp1#pharma